cyrilzakka/clinical-trials huggingface dataset:
Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a prevalent entity, affecting over 50% of men older than 60 years. The clinical picture of the disease includes lower urinary tract symptoms such as interrupted and weak urinary stream, nocturia, urgency and leaking and even sexual dysfunction in some individuals. Medical therapy is usually the first-line treatment. However, the efficacy of drugs like alpha-blockers is limited, and as disease progresses more invasive treatment options have to be taken into consideration. In cases with moderate to severe lower urinary tract symptoms (LUTS) transurethral resection of the prostate (TUR-P) is the standard treatment. TURP, however, is limited to prostates smaller than 60-80ml and the procedure is associated with a complication rate. The cumulative short-term morbidity rate is around 11% and the necessity for surgical revision is as high as 6%. Bleeding requiring transfusions and transurethral resection syndrome represent potentially serious threats to elderly and frail patients. Prostatic artery embolization (PAE) has been suggested as a minimal invasive alternative procedure, which can be performed in an outpatient setting with rapid recovery and low morbidity.

The investigators hypothesize that PAE is non-inferior in the treatment of symptomatic BPH compared to conventional and established TUR-P.


Eligibility Criteria:
Inclusion Criteria:

* Men older than 40
* Patient must be a candidate for TURP
* Refractory to medical therapy or patient is not willing to consider (further) medical treatment
* Patient has a prostate size of at least 25 ml and not more than 80 ml, measured by ultrasound
* IPSS ≥8
* QoL ≥3
* Qmax\<12 and/or urinary retention
* Written informed consent

Exclusion Criteria:

* Mild symptoms (IPSS \<8)
* Severe atherosclerosis
* Severe tortuosity in the aortic bifurcation or internal iliac arteries
* Acontractile detrusor
* Neurogenic lower urinary tract dysfunction
* Urethral stenosis
* Bladder diverticulum
* Bladder stone with surgical indication
* Allergy to intravenous contrast media
* Contraindication for MRI imaging
* Preinterventionally proven adenocarcinoma of the prostate
* Renal failure (GFR\<60ml/min)
The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease

The objectives of this study are the following: 1) to determine the effect of daily consumption of whole grain barley for six week on risk factors of cardiovascular disease compared to a diet low in whole grains, and 2) to compare the effects of daily consumption of whole grain barley to those of whole grain oats for six weeks to determine if the response to these two grains is different.


Eligibility Criteria:
Inclusion Criteria:

* Men and women between the ages of 25-70 years
* Body mass index (BMI) ≥ 19 and ≤ 38
* Willingness and ability to make scheduled appointments at clinical site as required by study protocol

Exclusion Criteria:

* Do not regularly consume breakfast or dislike cereal for breakfast
* Known (self-reported) allergy or adverse reaction to grains (e.g., wheat, gluten, barley)
* Presence of kidney disease, liver disease, gout, untreated or unstable hypothyroidism, untreated or unstable hyperthyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other metabolic diseases, or malabsorption syndromes
* Type 2 diabetes requiring the use of oral antidiabetic agents or insulin
* Fasting triglycerides \> 300 mg/dL
* Fasting glucose \> 126 mg/dL
* Use of cholesterol lowering medication
* Blood pressure \> 180/100 or hypertension treated with calcium channel blockers, direct acting vasodilators, or beta blockers
* History of bariatric or certain other surgeries related to weight control
* History of major surgery within 3 months of enrollment
* Smokers or other tobacco users (during 6 months prior to the start of the study)
* Antibiotic use during the intervention or for 3 months prior to the intervention period
* History of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets)
* Volunteers who have lost 10% of body weight within the last 6 months
* Unable or unwilling to give informed consent or communicate with study staff
* Self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)
* Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol
Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China

This is a retrospective, hospital-based and multi-center study aiming at investigating the potential exposures associated with the formation, progression, and rupture of intracranial aneurysms in Chinese population.

A striking conflict exists between the fatal rupture of intracranial aneurysms (IA) and the passive approach to detecting IA through cerebrovascular examinations. This is attributed to a limited understanding of risk factors for IA incidence and the resulting lack of cost-effective IA screening.

This study aims to gain epidemiological insights into the exposures associated with the risk of IA incidence, including formation, progression, and rupture in the Chinese population. It integrates multi-modal data based on large-scale electronic medical records from high-volume stroke centers across China to investigate potential associations between various exposures and IA incidence.

Patients with anonymous and unique IDs were screened for the presence of IA by formal readings from digital subtraction angiography (DSA), cranial computed tomography angiography (CTA), or magnetic resonance angiography (MRA) conducted by two radiologists, which were then confirmed by two treating neurosurgeons using the raw images. Using natural language processing in conjunction with medical records and multi-modal data, patient exposures were extracted and assumed to be absent if no documentation was found across the databases.

Through a series of retrospective analyses, we aim to identify the exposures associated with IA incidence as much as possible to gather valuable insights for future prospective research.

Eligibility Criteria:
Inclusion Criteria:

1. IA diagnosis (ruptured or unruptured) or exclusion by digital subtractive angiography (DSA) or by cranial computed tomography angiography (CTA) / magnetic resonance angiography (MRA);
2. Aged ≥ 18 and ≤ 18 years old;
3. With complete demographic data including age and sex;
4. With medical record archiving officially.

Exclusion Criteria:

1. Missing data of age, sex or hypertensive status;
2. Age \<18 or \>80 years;
3. Pregnancy;
4. With a history of intracranial arteriovenous malformation, Moyamoya, polycystic kidney disease, Ehlers-Danlos syndrome, Gronblad-Strandberg syndrome, or Marfan syndrome;
5. Suspicion for dissecting or mycotic aneurysms or aneurysm-like lesions that were indistinguishable from the infundibulum, fenestration, dilation, or atherosclerotic remodeling on structural imaging scans.
Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset) and other side effects related to regadenoson.

Approximately 250 patients who are referred for a nuclear stress testing of the heart with regadenoson (Lexiscan®) will be recruited to participate in the study. Following regadenoson (administered as part of a stress routine test protocol) participants will receive either aminophylline (75 mg - intravenously) or a matching inactive placebo (sterile salt water) injection. Participants will be surveyed for gastrointestinal symptoms and other side effects related to regadenoson. The frequency and severity of such side effects will be compared between the two study groups (aminophylline vs. placebo).

Eligibility Criteria:
Inclusion Criteria:

* Adult patients referred to undergo a clinically-indicated regadenoson-stress myocardial perfusion imaging at Rush University Medical Center

Exclusion Criteria:

* Patient refusal to participate
* Known allergic reaction to aminophylline.
* Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea, abdominal discomfort, nausea or vomiting.
* Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms.
* Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12 months or any seizure in the past week.
* Pregnant or breast-feeding women.
* Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).
Gestational Weight Gain in Primary Care

Excess weight gain in pregnancy is linked to a number of adverse outcomes for mothers and their offspring, and in 2011, 59 % of women in Nova Scotia gained weight in excess of recommendations. A number of factors influence how much weight a woman gains, including lack of knowledge, age, the number of previous pregnancies she's had, smoking, ethnicity, income, and education. Although a clinician's advice also plays a role, simply giving advice does not necessarily translate into patient behaviour change. On the other hand, advice that is given through a patient-centred approach is significantly associated with increased patient acceptance of and adherence to recommendations, and increased intentions and attempts at behaviour change. In addition, this approach has been shown to decrease costs to the health care system. Patient-centredness can measured from the perspective of the clinician, an observer, or the patient. Research suggests that the patient's perspective of patient-centredness is the perspective most significantly associated with improved health outcomes.

Clinicians avoid discussing weight-related matters for a number of reasons, including a lack of time and general discomfort in raising the subject. There are some tools that can address some of these barriers, and example being the "5As of Obesity Management". This tool is based on principles of behaviour change science and patient-centredness. Pilot data on the use of this tool showed a two-fold increase in the initiation of weight-related discussions between clinicians and their patients. Our team was instrumental in the development, dissemination and initial evaluation of this tool, and Dr. Piccinini-Vallis has recently led a national multidisciplinary endeavor to adapt it to pregnancy, which has resulted in the "5As of Healthy Pregnancy Weight Gain" tool. It is now time to evaluate whether the use of this tool is acceptable to clinicians and whether its use translates into any patient outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Family physicians providing prenatal care
* Patients who are pregnant

Exclusion Criteria:

* Multiple pregnancy
* Abnormal pregnancy
* Inability to read and inability to speak English
Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices

This study is conducted to assess the ease of device mastery of a placebo SYMBICORT TURBOHALER vs a placebo Budesonide/Formoterol SPIROMAX device among healthcare professionals in-training (HCP).

The purpose of this study is to identify how intuitive devices are to use and what level of training is required to ensure that HCPs are able to demonstrate the correct technique. The two devices examined will be the SYMBICORT TURBOHALER and placebo Budesonide/Formoterol SPIROMAX device among healthcare professionals (HCP).

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent is obtained and dated by the participant before conducting any study related procedures.
* The participant is a student that is currently enrolled in the University where the study is conducted
* The participant must be willing and able to comply with study restrictions and to remain at the study site for the required duration during the study period, and willing to return to the site for the follow up evaluation as specified in this protocol.
* The participant has not previously used or received training in the use of either the SPIROMAX or the TURBOHALER in the last 6 months

Exclusion Criteria:

* Participants will be excluded from participating in this study if they have asthma.
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

This is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of a single dose of warfarin.


Eligibility Criteria:
Inclusion Criteria:

* Motivated and available for duration of study and willing to adhere to protocol
* Males who are unable to procreate or agree to contraception throughout study
* Females who are postmenopausal or surgically sterile
* BMI between 18.5 and 30 kg/m2
* Weighing greater than or equal to 50kg
* Normal lab results
* No known diseases or significant findings on physical exam

Exclusion Criteria:

* Females of childbearing potential
* Reactions/infection at injection site
* Hypersensitivity to any drugs or similar drugs to those used in the study
* Conditions or disease that may interfere with study drug
* Any significant diseases
* Known history or familial history of bleeding disorders
* Drug dependency or abuse
* Illness within 28 days
* Previous exposure to other investigational drug within 28 days
* Blood donations within 28 days
To Evaluate the Efficacy of Capsimax on Metabolic Rate

Capsimax™ is a proprietary Capsicum Extract that employs Beadlet Technology. In the previous study it has been used to investigate its effect in reducing body fat/weight and increase metabolic rate. In this study, Capsimax™ will be used to assess effect on Resting Energy Expenditure (REE) using Indirect Calorimetry.


Eligibility Criteria:
Inclusion Criteria:

* Healthy, adult, male/female participants with age ≥ 18 ≤ 55 years.
* A Body Mass Index (BMI) between 18.5 to 29.9 kg/m2.
* Fasting blood sugar ≤ 100 mg/dl
* Hemoglobin: Males ≥ 11 g/dl and Females ≥ 10 g/dl
* BP \< 140/90 mmHg

Exclusion Criteria:

* Post-menopausal females
* History of hypo/ hyperthyroidism.
* History of significant neurological or psychiatric condition such as seizures, depression, or insomnia.
Association of Long-term Conditions With Survival Following Heart Attack in England and Wales

This study aims to determine the extent to which pre-existing long-term conditions are associated with survival following a heart attack (acute myocardial infarction) using observational data from the UK's national heart attack register.

Using observational data from the Myocardial Ischaemia National Audit Project (MINAP) of all hospitalisations for acute myocardial infarction in all acute hospitals in England and Wales, this study aims to determine the extent to which pre-existing long-term conditions are associated with survival following acute myocardial infarction. The study will include an investigation of individual long term conditions for patients with acute myocardial infarction, including chronic heart failure, cerebrovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic renal failure or peripheral vascular disease as well as the combination of such conditions and their resulting impact on long term all-cause mortality (up to 8.4 years). In addition, an investigation of the association of receipt of guideline recommended care for acute myocardial infarction patients with pre-existing long term conditions will be made.

Eligibility Criteria:
Inclusion Criteria:

* Patients must be 18 years or older

Exclusion Criteria:

* Patients for which mortality data are missing
Effects of Topical Cream for Pain Relief

To perform a clinical proof-of-concept study on a novel topical formula for pain relief.

An open-label study where each participant will be involved in the study for 4 weeks. During the study participants will use the topical cream 1-2 times daily on the anatomical area(s) causing the most pain.

Eligibility Criteria:
Inclusion Criteria:

* BMI between 18.5 and 34.9 kg/m2 (inclusive)
* Chronic joint/muscle related pain for at least past 6 months
* Experiencing chronic pain in at least one specific anatomical area for more than 6 months.

Exclusion Criteria:

* Cancer during past 12 months
* Chemotherapy during past 12 months
* Currently taking prescription pain medications
* Getting regular joint injections (such as cortisone shots);
* Immunization during last month
* Participation in another clinical trial study during this trial, involving an investigational product or lifestyle change
* Regularly experiencing headaches, including migraines
* Serious active illness within past 6 months
* Significant active uncontrolled illness (such as lymphoma, liver disease, kidney failure, heart failure).
* Skin allergies related to ingredients in test product.
A New Concept in the Tip Plasty of Asian Rhinoplasty

For achieving the desired refinements in Asian patients, sufficient septal cartilage must be needed for the ieal tip projection and lengthening of the nose by the septal extension graft, columellar septal strut graft, and onlay tip graft, shield graft. Actually there are many cases having insufficient septal cartilages in Asian augmentation rhinoplasty.

The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result.

The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result.

Eligibility Criteria:
Inclusion Criteria:

* primary case
* secondary case

Exclusion Criteria:

* septal cartilage harvested state
* congenital anomaly in septal cartilage
Evaluation of Visual Parameters by Visual Evoked Potentials Captured by EEG

This project will be based on an approach that has already proven itself in the field of the development of low-level visual functions such as visual acuity, vernier acuity and contrast sensitivity (Norcia \& Tyler, 1985): scanning visual evoked potentials" (sVEP), a special case of steady-state visual evoked potentials (SSVEP). While SSVEPs consist of presenting a visual stimulus periodically, sVEPs are SSVEPs where the value of a parameter (e.g. the contrast of the stimulus) varies. This variation ("scanning") makes it possible to determine the threshold value where an electroencephalographic (EEG) response is perceived, and thus to evaluate visual parameters such as visual acuity, vernier acuity and contrast sensitivity. In this study we therefore record the amplitude of the EEG electrical signal during the presentation of low-level stimuli such as spatial frequency gratings or increasing or decreasing contrast.


Eligibility Criteria:
Inclusion Criteria:

* Absence of ocular pathologies except for refractive errors
* Absence of neurologic conditions

Exclusion Criteria:

* Participants using neurologic or psychiatric drugs
* Scalp pathology
A Different Use of The Aerosol Box in COVID-19 Patients; Internal Jugular Vein Cannulation

During the COVID-19 pandemic, health employees are at high risk of infection. This study aimed to determine experiences with an aerosol box (AB), used with the aim of preventing contamination by droplets during internal jugular vein cannulation which requires close contact with COVID-19 patients, and the necessity to use this device.

The study included 40 patients with diagnosis of COVID-19 requiring central venous catheter during treatment in the ward. The patients were randomly allocated to one of the two protective equipment groups and, then, randomly assigned to one of the five clinicians. Group P\&A had both personal protective equipment (PPE) and AB used, while Group P included patients where PPE was used alone. Clinicians completed a survey after performing the procedure to evaluate the use of the aerosol box. Collected data of the procedures and patients, were analyzed. In addition, survey data were evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with COVID-19 and inserted central venous catheter while being treated in the ward

Exclusion Criteria:

* Patients under the age of 18 years
* Patients who can not lie in the supine position due to severe respiratory distress,
* Patients with thrombus in the right İJV in evaluation with US
Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations

The aim of this study is to identify genetic abnormalities and molecular pathways associated with the occurrence of CCAM.

Congenital lung malformations are rare diseases, characterized by the coexistence in the same individual of normal lung and localized lung malformation. Among these malformations, congenital cystic adenomatoid malformations (CCAM) represent the most important group, with an estimated incidence between 1/11 000 and 1/35 000 births. The precise mechanisms leading to these lung malformations remain poorly understood. This project aims to identify key genetic and/or molecular mechanisms associated with the occurrence of CCAM. CCAMs are collected during postnatal surgical resection. Parental agreement is required. A standardised histologic description of malformations is performed for each sample. Normal lung tissue at the periphery of the malformation is considered as control. Malformations will be analyzed in a systematic way by proteome and transcriptome, after laser microdissection. Somatic genetic abnormalities will also systematically be sought.

Eligibility Criteria:
Inclusion Criteria:

* Children \< 8 years
* Thoracic surgery for congenital lung malformation
* Parental written consent

Exclusion Criteria:

* Children \> 8 years
* Previous infection of the malformation
* Parental rebutal